For the roughly one-third of celiac disease patients who remain symptomatic despite strict gluten-free dieting, nutritional adjuncts have long been an underexplored frontier. This systematic review challenges the assumption that eliminating gluten is sufficient for gut restoration, presenting the strongest aggregated clinical evidence to date that targeted prebiotic strategies can meaningfully shift microbial and metabolic markers in this population.
Drawing on 12 clinical studies enrolling 1,066 participants and adhering to PRISMA methodology with Cochrane RoB 2.0 risk-of-bias assessments, the review identified several notable outcomes across prebiotic types. Oligofructose-enriched inulin (Synergy 1) drove a 31% increase in fecal short-chain fatty acid (SCFA) concentrations alongside elevated Bifidobacterium abundance, higher osteocalcin, improved serum vitamins D and E, and a striking 61% reduction in hepcidin — a key regulator of iron absorption — without triggering gastrointestinal intolerance. Oats consumed at 50–70 g per day for up to 24 months preserved histologic remission and supported improved intake of iron, fiber, thiamin, and zinc. Ancient grains also featured: quinoa modestly reduced cholesterol, while amaranth supplementation improved growth trajectories and corrected trace-element deficiencies specifically in pediatric patients.
The findings carry meaningful implications but warrant careful interpretation. Celiac disease induces a distinctively dysbiotic gut environment — reduced microbial diversity, depleted butyrate producers, and compromised epithelial barrier function — that a gluten-free diet alone incompletely reverses. The hepcidin reduction observed with inulin-type fructans is particularly noteworthy given that iron-deficiency anemia is among the most common and persistent complications in treated celiac patients. That said, this review synthesizes only 12 heterogeneous studies with varied designs, prebiotic sources, doses, and follow-up periods, precluding formal meta-analysis; the authors relied on narrative synthesis. No serious adverse events were reported across studies, which supports safety but does not substitute for adequately powered randomized trials. The field currently lacks large phase III trials, and most evidence remains exploratory or observational. This review is best understood as a well-organized signal-gathering exercise pointing toward inulin-type fructans as the most evidence-supported adjunct — incremental progress with a clear agenda for future trials.
